# US 8,277,823 B2 · Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,823 B2
- Document ID: US8277823B2
- Status: Granted
- Kind: B2
- Application number: 12/784,821
- Filed: 2010-05-21
- Published: 2010-09-09
- Granted: 2012-10-02
- Earliest claimed: 2004-07-07
- Assignees: Statens Serum Institut
- Inventors: Jesper Davidsen; Peter Andersen; Ida Rosenkrands
- Web page: https://patentgrep.com/patent/US8277823B2

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.

## Claims

### Claim 1

A method of stabilizing cationic liposomes in aqueous formulations comprising incorporating 2.5 mole % to about 95 mole % glycolipids into said cationic liposomes.

### Claim 2 (depends on 1)

The method of stabilizing cationic liposomes according to claim 1 where the cationic liposome comprises an amphiphilic quaternary ammonium compound.

### Claim 3 (depends on 2)

The method of stabilizing cationic liposomes according to claim 2 where the amphiphilic guaternary ammonium compound has one or two aliphatic chains.

### Claim 4 (depends on 2)

The method of stabilizing cationic liposomes according to claim 2 where the amphiphilic quaternary ammonium compound is DDA-B, DDA-C, DDA-X, DODA-B, DODA-C, DODA-X, DOTAP, DODAP or DOTMA.

### Claim 5 (depends on 1)

The method of stabilizing cationic liposomes according to claim 1 where the glycolipid is an acylated glycoside formed by one or up to three aliphatic hydrocarbon chains bound to one or two sugar residues.

### Claim 6 (depends on 5)

The method of stabilizing cationic liposomes according to claim 5 where the glycolipid is a disaccharide with two acyl chains.

### Claim 7 (depends on 5)

The method of stabilizing cationic liposomes according to claim 5 where the acyl chains comprise 15 to 90 C-atoms.

### Claim 8 (depends on 7)

The method of stabilizing cationic liposomes according to claim 7 where the glycolipid is alpha,alpha′-trehalose 6,6′ dibehenate (TDB) or alpha,alpha′-trehalose 6,6′-dimycolate (TDM).

### Claim 9 (depends on 1)

The method of stabilizing cationic liposomes according to claim 1 where the molar percentage of the particular glycolipid is from 2.5 mole % to about 20 mole.

### Claim 10 (depends on 1)

A cationic liposome product stabilized by the method of claim 1.

### Claim 11 (depends on 10)

The cationic liposome product according to claim 10 where an antigenic compound is encapsulated in the liposomes.

### Claim 12 (depends on 10)

The cationic liposome product according to claim 10 formulated for use in drug delivery.

### Claim 13 (depends on 11)

The cationic liposome product according to claim 11 formulated for use as an adjuvant.

### Claim 14 (depends on 13)

A vaccine adjuvant comprising the cationic liposome product according to claim 13 and an immunomodulator.

### Claim 15 (depends on 14)

The vaccine adjuvant according to claim 14, wherein the immunomodulator is selected from the group consisting of monophosphoryl lipid A (MPL), derivatives of MPL, myramyl dipeptide (MDP), analogs of MDP, zymosan, double-stranded RNA (ds-RNA), cholesteryl-3(β)-N-[dimethylaminoethyl] carbamate (DC-Chol), CpG oligodeoxynucleotides, and tamoxifen.

### Claim 16 (depends on 14)

The vaccine adjuvant according to claim 14, wherein the immunomodulator is polyinosinic polycytidylic acid.

### Claim 17 (depends on 1)

The method of stabilizing cationic liposomes according to claim 1 where the molar percentage of the particular glycolipid is from about 5 mole % to about 18 mole %.

### Claim 18

A method of stabilizing cationic liposomes in aqueous formulations comprising incorporating 2.5 mole % to about 20 mole % glycolipids selected from the group consisting of alpha,alpha′-trehalose 6,6′ dibehenate (TDB), alpha,alpha′-trehalose 6,6′ dimycolate (TDM), a ceramide and a ganglioside into the cationic liposomes prepared from dimethyldioactadecylammonium (DDA) chloride.

### Claim 19 (depends on 18)

The method of stabilizing cationic liposomes according to claim 18 where the molar percentage of the particular glycolipid is from about 5 mole % to about 18 mole %.

### Claim 20 (depends on 18)

The method of stabilizing cationic liposomes according to claim 18 where the glycolipid is TDB.
